Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data by San Román, L. et al.
  
 
UPCommons 
Portal del coneixement obert de la UPC 
http://upcommons.upc.edu/e-prints 
 
 
Aquesta és una còpia de la versió author’s final draft d'un article 
publicat a la revista The Lancet Neurology. 
URL d'aquest document a UPCommons E-prints: 
http://hdl.handle.net/2117/123603 
 
 
Article publicat / Published paper: 
San Román, L., Menon, B., Blasco, J., Cobo, E. Imaging features and 
safety and efficacy of endovascular stroke treatment: a meta-analysis 
of individual patient-level data. "The Lancet Neurology", 1 Octubre 
2018, vol. 17, núm. 10, p. 895-904. Doi: 10.1016/S1474- 
4422(18)30242-4 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326.  
1 
Imaging features and safety and efficacy of endovascular stroke treatment: an individual pa-
tient data meta-analysis  
Luis San Roman, MD1*, Bijoy K Menon, MD2*, Jordi Blasco, MD1, María Hernández-Pérez, MD3, 
Antoni Davalos, MD3, Charles Majoie, MD4, Bruce C.V. Campbell, MD5, Francis Guillemin, MD6, 
Hester Lingsma, PhD7, René Anxionnat, MD8, Jonathan Epstein, MD6, Jeffrey L. Saver, MD9, 
Henk Marquering, PhD10, John H. Wong, MD2, Demetrius Lopes, MD11, Gernot Reimann, MHBA 
12, Hubert Desal, MD13, Diederik W.J. Dippel, MD14, Shelagh Coutts, MD2, Richard du Mesnil de 
Rochemont, MD15, Dileep Yavagal, MD 16, Jean Christophe Ferre, MD 17, Yvo B. W. E. M Roos, 
MD 18, David S. Liebeskind, MD 19, Robert Lenthall, MD 20, Carlos Molina, MD 21, Fahad S Al Aj-
lan, MD 22, Vivek Reddy, MD 23, Dar Dowlatshahi, MD 24, Sourour Nader-Antoine, MD 25, Cathe-
rine Oppenheim, MD 26, Alim Mitha, MD 2, Stephen M. Davis, MD 5, Christian Weimar, MD 27, 
Robert J. van Oostenbrugge, MD 28, Erik Cobo, MD 29, Timothy J. Kleinig, PhD 30, Geoffrey A. 
Donnan, MD 31, Aad van der Lugt, MD 32, Andrew Demchuk, MD 2, Olvert A. Berkhemer, MD
14,32,33,39 , Anna M. M. Boers, MSc34, Gary A. Ford, FMedSci 35, Keith Muir, MD 36, B. Scott 
Brown, PhD 37, Tudor Jovin, MD 38, Wim H. van Zwam, MD 39, Peter J. Mitchell, MD 40, Michael 
D Hill, MD 2, Phil White, MD41, Serge Bracard, MD42, Mayank Goyal, MD2 on behalf of the 
HERMES collaborators. 
LsR and BKM have contributed equally* 
1 Department of Interventional Neuroradiology CDI Hospital Clinic of Barcelona, Spain 
2Department of Clinical Neurosciences and Radiology, Cumming School of Medicine, University 
of Calgary, Foothills Hospital, Calgary AB, Canada  
3Department of Neuroscience, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 
Barcelona, Spain 
4Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the 
Netherlands 
5Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospi-
tal, University of Melbourne, Parkville, Australia 
6INSERM CIC 1433 Clinical Epidemiology, Université de Lorraine and University Hospital of 
Nancy, Nancy, France 
7Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands 
8Department of Diagnostic and Interventional Neuroradiology, INSERM U 947, Université de Lor-
raine and University Hospital of Nancy, Nancy, France 
9Department of Neurology, David Geffen School of Medicine at the University of California, Los 
Angeles, Los Angeles, California, USA  
10Department of Biomedical Engineering and Physics, Academic Medical Center, the Netherlands 
11Department of Neurosurgery and Radiology, Rush University Medical Center, Chicago, Illinois  
12 Stroke-Unit und Neurologische Intensivstation, Klinikum Dortmund gGmbH, Dortmund, 
Germany 
13Department of Neuroradiology, University and University Hospital of Nantes, France 
14Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands 
15Department of Radiology, University Hospital, Frankfurt, Germany 
16Department of Neurology and Neurosurgery, University of Miami Miller School of Medicine–
Jackson Memorial Hospital, Miami, USA  
17Department of Neuroradiology, University of Rennes 1 and University Hospital Rennes, France 
18Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands 
19Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at 
the University of California, Los Angeles, Los Angeles, California, USA  
20Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, UK 
21 Stroke Unit, Vall d'Hebrón Hospital, Barcelona, Spain 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326.  
 
 2 
22Department of Medicine (Neurology), University of Ottawa, Canada 
23 Department of Neurology, Drexel University College of Medicine Philadelphia, PA 
24Department of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Insti-
tute, Canada 
25 Department of Neuroradiology. Pitié-Salpêtrière Hospital. APHP. Paris. France 
26 Department of Neuroradiology, Sainte-Anne Hospital and Paris-Descartes University, INSERM 
U894, Paris, France 
27 Department of Neurology and stroke unit, University of Essen, Germany 
28Department of Neurology, Maastricht, the Netherlands  
29Barcelona-Tech, Barcelona, Spain 
30 Department of Neurology Royal Adelaide Hospital Adelaide Australia 
31The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Aus-
tralia 
32Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rot-
terdam, The Netherlands. 
33Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the 
Netherlands 
34 Departments of Biomedical Engineering and Physics, Radiology and Nuclear Medicine, Academ-
ic Medical Centre, Amsterdam, the Netherlands 
35 Consultant Physician, Oxford University Hospitals NHS Foundation Trust, Oxford Science Park, 
Oxford, UK 
36Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University 
Hospital, Glasgow, UK 
37Altair Biostatistics, St Louis Park, Minnesota, USA 
38Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, 
USA 
39Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands 
40Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Aus-
tralia 
41Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK  
42Department of Diagnostic and Interventional Neuroradiology, INSERM U 947, University of Lor-
raine and University Hospital of Nancy, Nancy, France 
Acknowledgements and Funding: 
The study sponsor is the University of Calgary. Major funding is provided through an unrestricted 
grant from Medtronic. The funders of the study had no role in study design, data collection, data 
analysis, data interpretation, or elaboration of the report. All authors had full access to all data in the 
study. The HERMES Steering Committee has responsibility for the decision to submit for 
publication. The corresponding author has final responsibility. 
Correspondence to: 
Mayank Goyal, MD, FRCPC, FAHA 
Seaman Family MR Research Centre,  
Foothills Medical Centre,  
1403 - 29th St. NW, Calgary, AB T2N 2T9, Canada 
Ph: 403 944 3379; Fax: 403 270 7907; mgoyal@ucalgary.ca 
 
Cover title:Imaging features and safety and efficacy of endovascular stroke treatment: an 
individual patient data meta-analysis  
Keywords: acute ischemic stroke, endovascular therapy, imaging, CT, MRI 
Word Count: Abstract 302; Research in context : 290 ;  Manuscript text : 2944 
Figures: 3; Tables:2; Supplementary Material:1 
 
 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326.  
 
 3 
 
SUMMARY  
 
Background  
 
We aimed to investigate baseline-imaging features associated with efficacy and safety of endovas-
cular thrombectomy (EVT) in acute ischaemic stroke caused by anterior large vessel occlusion. 
 
Methods  
 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration identified 7 trials (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, RE-
VASCAT, THRACE and PISTE). The risk of bias and variability among studies was assessed to be 
low, using the Cochrane tool. 
Central, blinded readers rated baseline imaging for ischemic change using the Alberta Stroke Pro-
gram Early Computed Tomography score (ASPECTS) or ischemic change involving > 1/3 of mid-
dle cerebral artery territory, thrombus volume, hyperdensity, and collateral status. Primary func-
tional endpoint was the modified Rankin Scale (mRS) score at 90 days. 
 
Findings  
Among 1764 pooled patients, 871 were allocated to the EVT arm and 893 to control. The overall 
treatment effect favored EVT (adjusted common Odds Ratio 2·00, 95% CI 1·69–2·38; p<0·0001) 
and limited heterogeneity of benefit was observed   across all pre-specified imaging strata, includ-
ing patients with low ASPECTS 0-4, > 1/3 MCA territory infarct, poor collaterals and all levels of 
clot burden. Higher risk of symptomatic intracranial hemorrhage (sICH) was seen in patients with 
ASPECTS 0-4 (19·2% versus 4·5%, adjusted common Odds Ratio 3·94, 95% CI 0·94–16·49, inter-
action P= 0·025) and with > 1/3 MCA territory infarct (13·9% versus 3·5%, adjusted common Odds 
Ratio 4·17, 95% CI 1·3–13·44, interaction P=0·012) when allocated EVT. In sensitivity analysis to 
determine the optimal lower cut-point for baseline ASPECTS, patients with baseline ASPECTS as 
low as 3 showed benefit with EVT.  
 
Interpretation  
EVT achieves better 90 day outcomes than medical therapy alone across a broad range of baseline 
imaging categories including patients with large infarcts. 
 
Funding Unrestricted grant from Medtronic.  
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Research in context   
 
Evidence before the study: 
 
Recent randomized trials have demonstrated the efficacy of endovascular thrombectomy (EVT). 
The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration published in Feb 2016 a pooled analysis of individual patient-level data of the first 
five randomized trials of endovascular thrombectomy. It confirmed benefit of endovascular 
thrombectomy across a wide range of clinical subgroups and reported on the effect of ASPECTS 
and site of vessel occlusion as assessed by each individual trial. However, evidence regarding utility 
of imaging in selecting patients for EVT is limited. 
                                                                                     
 Added value of this study  
 
This is the first individual level meta-analysis using imaging data obtained through single core lab 
analysis from all seven randomized endovascular stroke trials listed in PubMed (1/Jan/2010-
31/October/2017) comparing EVT to standard medical therapy in patients with acute ischemic 
stroke and anterior circulation large vessel occlusion. 
Trials requiring imaging to identify patients with anterior circulation ischemic stroke and using sec-
ond-generation neuro-thrombectomy devices in the EVT arm were included. It represents a unique 
dataset that is unlikely to ever be replicated in the future, as randomized trials of thrombectomy for 
large vessel occlusion stroke in the patient population studied by these trials are no longer consid-
ered ethically justifiable. 
This meta-analysis provides new and substantial evidence that patients with a broad range of base-
line imaging characteristics including those with larger infarcts, poor collaterals and any clot burden 
score benefit from endovascular thrombectomy (EVT).       
Implications of all the available evidence 
Current guidelines by the American Heart Association (AHA) recommend EVT in patients with 
ASPECTS>5. This analysis provides evidentiary support for expansion of existing practice guide-
lines to endorse, in a qualified manner, EVT even for patients with large infarcts at baseline (AS-
PECTS as low as 3). 
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INTRODUTION 
Recent randomized clinical trials have established the efficacy and safety of endovascular 
thrombectomy (EVT) in the treatment of patients with acute ischemic stroke and proximal anterior 
circulation occlusion.1-8 Because clinical benefit observed in these trials is time dependent, the need 
for fast and efficient patient selection is well recognized.9 Imaging is widely used to determine 
prognosis and to select patients for EVT.10-12 After the results of the five trials reported in 2015, the 
new AHA guidelines recommend EVT as standard of care (Level I, Class A evidence) in patients 
with baseline non-contrast CT ASPECTS 6-10.13 
 
Imaging features are strong predictors of clinical outcome.10 Large infarcts at baseline, large 
thrombus in proximal arteries and poor collateral circulation identified using imaging are overall 
associated with lower likelihood of functional dependence and increased risk after reperfusion 
therapies.14-19 However, evidence regarding the utility of these imaging features in selecting patients 
for EVT is limited. This patient level meta-analysis of the HERMES (Highly Effective Reperfusion 
evaluated in Multiple Endovascular Stroke Trials) Collaboration aims to determine baseline-
imaging features associated with efficacy and safety of EVT when compared to standard medical 
therapy.  
 
 
METHODS 
Study design and participants  
We searched Pubmed for randomized trials published between 1 Jan 2010 and 31 October 2017 
comparing endovascular thrombectomy performed using predominantly stent-retrievers with stand-
ard care in anterior circulation ischaemic stroke patients - Pubmed search string: (("randomized 
controlled trial"[Publication Type]) AND ((thrombectomy [Title/Abstract]) OR (clot retrieval [Ti-
tle/Abstract]) OR intraarterial[Title/Abstract]) AND (stroke[Title/Abstract]) AND 
("2010/01/01"[Date - Publication] : "2017/10/31"[Date - Publication])). 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration pooled patient level demographic, clinical and imaging data as well as functional and 
radiologic outcomes from 7 randomized trials: MR CLEAN, ESCAPE, EXTEND-IA, SWIFT 
PRIME, REVASCAT, THRACE and PISTE  (Supplement eFigure 1). All these trials required ves-
sel imaging to identify patients with anterior circulation ischemic stroke and used predominantly 
stent retrievers or second-generation neuro-thrombectomy devices in the EVT arm. Data were as-
sessed for quality and validity using PRISMA guidelines. Differences in patient population, sam-
pling frame and operational definitions of intervention (EVT) and control were assessed before col-
lating all data at a patient level (Supplement eTable 1). Risk of bias in the individual studies was 
assessed using the Cochrane handbook methodology and was low overall except in the THRACE 
study that used un-blinded assessment of 90-day outcome. In addition, in contrast to other studies, 
the THRACE study used MRI predominantly as the primary baseline imaging tool. This meta-
analysis was prospectively designed by the HERMES executive committee but not registered. All 
participants provided informed consent according to each trial protocol and each study was ap-
proved by the local ethics board. The methodological design for this patient level pooling has been 
previously described.8  
Imaging variables 
Baseline images included information available either on Computed Tomography (CT) or on 
Magnetic Resonance Imaging (MRI). All imaging studies were de-identified at the HERMES 
central coordinating center. The imaging datasets were then read by independent HERMES core 
labs for baseline CT/MRI, baseline CT Angiography (CTA), MRI Angiography (MRA), follow up 
CT or MR, and conventional angiography. Readers were blinded to all clinical information, except 
side of stroke.  
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Imaging in acute ischemic stroke is used to identify extent of early ischemic change and location 
and extent of thrombus. Pre-specified baseline imaging features of interest therefore were:  
1. The Alberta Stroke Program Early CT Score (ASPECTS) defined on CT or MR Diffusion 
Weighted Imaging (MR-DWI). This widely used ordinal scale measures extent of ischemia 
in the middle cerebral artery (MCA) territory (from score 0 in complete infarction to 10 for 
no infarction) .20 An ASPECTS region was considered as involved on DWI if the lesion 
occupied > 30% of the respective region, and on CT if any signs of ischemia were visible on 
at least two consecutive cuts of the 10 standardized regions of the MCA territory. ASPECTS 
grading was evaluated independently by two experts with more than 5 years of dedicated 
neuroradiology experience, blinded to all clinical and imaging information except stroke 
side. Any disagreement was resolved by consensus (inter-rater agreement Kappa 0·89, 95% 
CI 0·81 to 0·99). 
2. The > 1/3rd MCA rule defined on CT or MR-DWI as early ischemic change in > 1/3rd of the 
ischemic MCA territory.21 
3. Thrombus location identified on CTA or MRA. Thrombus location was classified as that in 
the intracranial internal carotid artery (ICA), proximal M1 middle cerebral artery (MCA) 
segment, distal M1 MCA segment and M2 MCA segment. Tandem occlusion was defined as 
thrombus in extracranial ICA along with intracranial (ICA, M1-MCA, M2-MCA) 
thrombus.22 
4. Collateral circulation distal to intracranial thrombus. Collateral circulation was evaluated on 
multi-phase CTA, single phase CTA or contrast-enhanced MRA and classified according to 
a previously published pre-specified collateral grade category (grade 0-1, poor; grade 2, 
intermediate; grade 3, good).19 
5. Thrombus density on imaging identified using assessment of the hyperdense artery sign on 
CT 23 and thrombus volume on CTA, analyzed using the clot burden score (CBS).24 
Data on number of patients assessed for each imaging variable at baseline and reasons for exclusion 
are described in Supplement eTable 2. Patients were excluded from further analyses if images were 
unavailable from primary trial or were of poor quality. 
 
Outcomes 
The primary endpoint was neurological functional disability scored on the modified Rankin Scale 
(mRS) 90 days after randomization with categories 5 (severe disability) and 6 (death) collapsed into 
a single category. Secondary efficacy outcomes were functional independence (mRS 0–2) at 90 
days, excellent functional outcome (mRS 0–1) at 90 days and dramatic neurological improvement 
(defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after 
stroke). Safety outcomes included intracranial hemorrhage defined as both symptomatic intracranial 
hemorrhage (sICH; defined by each trial), parenchymal hematoma type 2 (PH2; blood clot 
occupying >30% of the infarcted territory with substantial mass effect) within 5 days of 
randomization, and mortality within 90 days. 
 
Statistical analysis 
All analyses were based on the “as randomized” population. Unless otherwise stated, all reported 
analyses were pre-specified in the Statistical Analysis Plan. (Supplementary Material) To account 
for between trial differences when pooling patient level data, mixed-effects modeling was used for 
all analyses, with fixed effects for parameters of interest and “trial” and the interaction term 
“trial*treatment” as random effects variables in all models.8 Ordinal logistic regression models 
included fixed effects (age, sex, NIHSS score at admission, intravenous alteplase use and time from 
onset to randomization) and multiplicative interaction terms to test if pre-specified baseline-imaging 
features modified the effect of treatment allocation on pre-defined outcomes.  ASPECTS scores 
were trichotomized as 0-4, 5-7 and 8-10 for primary analysis.  In addition, as pre-specified in the 
Statistical Analysis Plan, an attempt was made to analyze treatment effect across each ASPECTS 
grade to identify an ASPECTS grade below which endovascular treatment may be considered futile 
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or potentially harmful.13 Sensitivity analyses were performed according to the primary imaging 
modality (CT or MRI) used at baseline. When missing (n= 21), the primary outcome was imputed 
as per methods pre-specified in each of the trials. All statistical analyses were performed using SAS 
v.9.2 (SAS Institute, Cary, North Carolina). 
 
Data sharing  
Anonymized Individual Participant Data (IPD) are already available in VISTA-endovascular, an 
open access registry (http://www.vista.gla.ac.uk)  
 
Role of the funding source 
An unrestricted grant was provided to the University of Calgary by Medtronic who had no role in 
study design, the collection, analysis or interpretation of data, the writing of the report or the deci-
sion to submit the paper for publication. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
We obtained data from the 1764 randomized participants, 871 patients assigned to endovascular 
thrombectomy (intervention population) and 893 assigned to standard medical treatment (control 
population). Pre-randomization brain imaging features were evaluated in 1388 patients on CT and 
in 364 patients on MRI. (Supplementary material Figure S2) Clinical characteristics and imaging 
features at baseline were balanced between the two treatment groups, but treatment with 
intravenous alteplase was more frequent in the control group (Table 1). 
 
Treatment with EVT was associated with reduced disability at 90 days (adjusted common Odds 
Ratio for a shift in direction towards a better functional outcome on the mRS 2·00, 95% CI 1·69–
2·38; p<0·0001). Figure 1 shows the effect of EVT vs. control on mRS at 90 days stratified by pre-
specified baseline imaging features. Distribution of 90-day mRS by treatment group and baseline 
imaging features are shown in Supplement eFigures 3-8. A treatment effect favoring EVT over 
control was observed in a broad range of pre-specified imaging strata. (Figure 1) .The treatment 
effect favored EVT over standard treatment across all three ASPECTS (0-4, 5-7, 8-10) categories 
(interaction p value=0·054). Treatment effects favoring EVT over control were observed in both the 
CT and the MRI sub-groups. (Supplement eFigure 9). In analysis of treatment  effect across each 
individual ASPECTS grade, since point estimates for treatment effect likely favored EVT for each 
individual ASPECTS grades except 0-2, an exploratory analyses informed by potential direction of 
treatment effect across each individual ASPECTS grade was attempted. In this analysis, statistically 
significant treatment effect favoring EVT were seen in patients with baseline ASPECTS 6-10 and 
3-5. The point estimate of treatment effect (common odds ratio) was < 1 in the ASPECTS 0-2 group 
(n=37); however, no statistically significant interaction for treatment effect size was noted across 
the three exploratory ASPECTS categories (6-10, 3-5, 0-2) (interaction p value = 0.30) (Figure 2) 
 
Table 2 summarizes results for secondary outcomes. A beneficial effect of EVT over control was 
seen across all imaging features for most pre-specified secondary outcomes. A statistically 
significant interaction between treatment effect and clot burden score was found for functional 
independence and dramatic neurological recovery at 24 hours (patients with more extensive 
thrombus at baseline likely benefit more with EVT); however, point estimates for treatment effect 
favored EVT across all strata. 
 
In analysis of safety outcomes, no statistically significant difference was noted in 90-day-mortality 
(14·7% vs. 17·3%, p value = 0.15), sICH (3·8% vs. 3·5%, p value = 0.90) and PH2 (5·6% vs. 4·8%, 
p value = 0.52) between EVT and control group.  No treatment effect modification by baseline 
imaging features was noted for 90-day-mortality and PH2 (Figure 3 and Supplementary Material 
Figure S9). When considering intracranial hemorrhage, results were inconsistent.  EVT was 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326.  
 
 8 
associated with a higher risk of sICH in patients with low ASPECTS (0-4) (adjusted common Odds 
Ratio 3·94, 95% CI 0·94–16·49, interaction P= 0·025) and in patients with baseline early ischemic 
change in > 1/3 of the MCA territory (adjusted common Odds Ratio 4·17, 95% CI 1·3–13·44, 
interaction P=0·012) but not when the outcome was purely radiological using PH2. (Figure 3 and 
Supplement eFigure 10). No interaction was observed with thrombolysis or no thrombolysis in this 
group of patients. Among patients with ASPECTS 0-4, sICH was observed in 10/52 (19·2%) 
patients in the EVT group vs. 3/56 (4·5%) patients in the control group (p value = 0·016). Similarly, 
sICH was observed in 15/108 (13·9%) patients in the EVT group vs.4/113 (3·5%) patients in the 
control group among patients with baseline early ischemic change in > 1/3rd of the MCA territory 
(p value = 0·007 (Table 3).  
 
DISCUSSION 
Our patient level meta-analysis supports the benefit of EVT for acute ischemic stroke across a broad 
range of imaging sub-groups.  Our results complement and add to previous work from the 
HERMES Collaboration that demonstrated benefit of EVT across a broad range of clinical 
subgroups.8 Our analysis is larger than this previous work (7 trials instead of 5, 1764 patients 
instead of 1287), uses more rigorous imaging analysis (HERMES core lab uniform re-reading of all 
scans from all trials), and analyzes key imaging subgroups not previously analyzed. Our results 
suggest that the prevailing opinion of futility associated with EVT in patients with larger infarcts 
identified on baseline imaging may not be appropriate, at least among patients otherwise deemed 
eligible to participate in the component clinical trials of the collaboration. We show benefit with 
EVT over standard care even in patients with low baseline ASPECTS. Our findings are in line with 
recent CT perfusion based studies derived from the same cohort of patients, which were also not 
able to identify baseline ischemic core volumes associated with treatment futility.25 
 
EVT is offered to patients with acute ischemic stroke when there is a target artery occlusion and 
what is presumed to be salvageable brain beyond that occlusion, based on interpretation of various 
imaging modalities.26 Thrombus in proximal intracranial arterial segments like in the ICA and M1 
MCA are more easily reached by current EVT than thrombus in more distal arterial segments.10 
Proximal intracranial arterial segment thrombi are also larger in volume (greater clot burden) than 
more distal thrombi. Unlike EVT therefore, intravenous alteplase is less likely to recanalize 
proximal thrombi early when compared to thrombi in distal arterial segments.27 Moreover, patients 
with thrombi in proximal intracranial arterial segments are likely to have greater amount of brain 
tissue at risk than patients with more distal thrombi. . 
 
Imaging is also used to identify extent of irreversibly injured brain tissue beyond target artery 
occlusion. Patients with large extent of irreversibly injured brain are less likely to have brain tissue 
that is salvageable with EVT.10,14,16 Both ASPECTS and the 1/3rd MCA rule identify extent of 
probably irreversibly injured brain on CT or MRI.20,23 Our analysis suggests relative treatment 
benefit with EVT across all ASPECTS categories and in patients with brain infarcts occupying > 
1/3rd of the ischemic MCA territory. The effect size by ASPECTS categories is however graded, 
with larger effect sizes noted in patients with higher ASPECTS.  Despite evidence of treatment 
benefit, the prognosis for patients with low ASPECTS remains poor with few achieving 
independent outcomes.  We also note, in post-hoc analysis, a statistically significant benefit with 
EVT even in patients with baseline ASPECTS 3-5, an ASPECTS category that until now may have 
been considered as indicative of treatment futility.13 Faster and better reperfusion techniques 
available since the HERMES trials, may magnify potential benefit in these patients from EVT.28 
The number of patients with ASPECTS 0 (n=12), 1 (n=13), 2 (n=12) in our analyses was very few; 
this is also the only imaging sub-group where the point estimate for treatment effect does not favor 
EVT. Ongoing clinical trials like TENSION and IN EXTRMEIS are likely to provide evidentiary 
support for or against net benefit of thrombectomy in patients with large ischemic core at baseline. 
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Patients with good collateral circulation status beyond target arterial occlusion are more likely to 
have salvageable brain than patients with poorer collaterals.29 CTA (or MRA) is often used to 
identify patients with poor collateral circulation. The technique therefore complements CT/MRI by 
identifying patients with large extent of irreversibly injured brain tissue. The ESCAPE trial used 
collateral circulation status to exclude patients with poor collaterals; other trials like SWIFT-
PRIME and EXTEND-IA used CT Perfusion or MR Perfusion, techniques that are based on the 
same principle of blood flow imaging that collateral assessments are based on, for selecting patients 
for those trials.3,4,7 Like ASPECTS and the 1/3rd MCA rule on CT/MRI, our analyses suggests 
benefit with EVT across all strata of collateral circulation status; however, patients with poor 
collaterals are less likely to benefit with EVT than those with better collaterals. Assessment of poor 
collateral circulation using dynamic angiographic techniques (rather than the single-phase CTA or 
MRA used in a majority of patients in our analyses) may help better identify patients unlikely to 
benefit with EVT.30  
 
Finally, imaging is used to determine risk with treatment. Our analyses suggest that sICH rates are 
four times more common in patients with ASPECTS 0-4 and hypodensity in > 1/3rd of the ischemic 
MCA territory. This increase in sICH rates with EVT was not influenced by age, baseline stroke 
severity or intravenous alteplase use. A net beneficial effect of EVT was, however, still seen in 
these patients. In routine practice, extensive early ischemic change should prompt consideration of 
risk benefit balance in patients who do not conform to trial characteristics. 
 
Our study has limitations. Since five out of the seven HERMES trials used baseline imaging criteria 
to exclude patients likely to have large infarcts, we therefore had relatively few patients with such 
imaging signatures in our analyses. Our results are reasonably consistent across both CT and MRI, 
and the sensitivity analyses suggest similar effects but could not confirm a significant benefit of 
thrombectomy in patients with largest baseline infarcts when assessed separately by either CT or 
DWI MRI, so confirmatory randomized trials may be necessary. The central re-analysis of images 
in the meta-analysis may not reflect the quality of on-site assessments. There was heterogeneity in 
the use of imaging tools, techniques and scanners in our study.10 This heterogeneity is however 
reflective of real world practice. 
 
In summary, in the first individual patient level meta-analysis analyzing the utility of baseline 
imaging in patients eligible for EVT, we found limited evidence of heterogeneity of treatment effect 
across imaging subgroups. Our analysis suggests that estimated treatment effect for EVT should be 
weighted in conjunction with other predictors of outcome when deciding whether or not to offer 
therapy to patients with large baseline infarcts. 
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TABLES 
 
Variables  Endovascular group (N=871)  Control group (N=893) 
Age in years (Median, Range)  67.4 (23.1, 92.5)  67.8 (18.0, 96.7) 
Female Sex (%)  47.3% (412/871)  47.3% (421/891) 
NIHSS at baseline (Median, Range)  [17] (3, 30)  [17] (4, 38) 
Onset to randomization in minutes (Median, Range)  [181] (49, 713)  [184] (37, 708) 
Intravenous alteplase (%)  87.6% (763/871)  90.6% (809/893) 
Baseline ASPECTS (Median, Range)  [8] (0, 10)  [8] (0, 10) 
Clot burden score (Median, Range)  [4] (0, 9)  [4.0] (0, 10) 
MCA > 1/3 involvement (%)  13.3% (114/860)  13.6% (119/876) 
Hyperdense vessel sign (%)  51.8% (356/687)  47.1% (330/701) 
Thrombus location (%)       
   ICA  26.3% (215/818)  27.4% (227/828) 
   Proximal M1 MCA  38.5% (315/818)  39.5% (327/828) 
   Distal M1 MCA  27.0% (221/818)  25.4% (210/828) 
   M2 MCA   8.2% (67/818)   7.7% (64/828) 
Collateral circulation grade (%)       
0   0.9% (6/639)   1.2% (8/651) 
1  14.2% (91/639)  16.6% (108/651) 
2  44.3% (283/639)  42.2% (275/651) 
3  40.5% (259/639)  39.9% (260/651) 
NIHSS, National Institute of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral 
Artery. 
Table 1: Baseline clinical and imaging variables by treatment groups. 
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   mRS 0-2  mRS 0-1  Dramatic neurological im-provement at 24h*  NIHSS 0-2 at 24h 
   EVT (%) 
Con-
trol 
(%) 
OR (95% 
CI) 
p-
val-
ue 
EVT 
(%) 
Con-
trol 
(%) 
OR (95% 
CI) 
p-
val-
ue 
EVT 
(%) 
Con-
trol 
(%) 
OR (95% 
CI) 
p-
val
ue 
EV
T 
(%) 
Con-
trol 
(%) 
OR 
(95% 
CI) 
p-
val-
ue 
Imaging Subgroups ( CT OR MR IMAGIG MODALITY) 
All 
subjects 
[n=1743] 
47.8
%  30.6% 
2.32 
(1.87-
2.87)  NA 
29.3
%  16.6% 
2.29 
(1.74-
3.01)  NA 
49.5
%  23.8% 
3.20 
(2.59-
3.96)  NA 
20.0
%  9.3% 
2.91 
(2.13
-
3.96) 
 NA 
AS-
PECTS 0 
to 4 
[n=126] 
24.6
%  14.5% 
2.72 
(0.89-
8.33) 
0.30
8 
15.8
%  5.8% 
9.10 
(0.96-
86.76) 
0.25
1 
31.4
%  10.8% 
4.62 
(1.61-
13.25) 
0.5
16 
2.0
%  1.6% 
0.05 
(0.00
-267) 
0.55
7 
AS-
PECTS 5 
to 7 
[n=615] 
43.6
%  29.4% 
2.07 
(1.43-
2.99) 
22.7
%  15.9% 
1.61 
(1.04-
2.48) 
43.8
%  19.4% 
3.34 
(2.28-
4.88) 
13.8
%  6.6% 
2.68 
(1.47
-
4.91) 
AS-
PECTS 8 
to 10 
[n=975] 
53.8
%  34.0% 
2.56 
(1.93-
3.40) 
35.6
%  18.9% 
2.64 
(1.89-
3.68) 
55.4
%  28.7% 
3.19 
(2.42-
4.20)  26% 
12.0
% 
3.06 
(2.12
-
4.42) 
AS-
PECTS 0 
to 2 
[n=37] 
0.0%  11.5% 
0.00 
(0.00-
5.81) 
0.69
5 
0.0% 0.0% NA 
0.87
9 
10.0
% 
12.5
% 
0.63 
(0.03-
14.11) 
0.7
56 
0.0
% 
0.0
% NA 
0.86
4 
AS-
PECTS 3 
to 5 
[n=186] 
30.6
%  15.6% 
4.27 
(1.62-
11.25) 
16.3
% 8.9% 
2.76 
(0.86-
8.86) 
28.1
% 8.2% 
5.53 
(2.06-
14.84) 
6.8
% 
3.6
% 
1.70 
(0.32
-
9.15) 
AS-
PECTS 6 
to 10 
[n=1493] 
51.0
%  33.4% 
2.29 
(1.83-
2.88) 
31.6
% 
18.4
% 
2.25 
(1.69-
2.99) 
52.7
% 
26.4
% 
3.16 
(2.53-
3.95) 
21.8
% 
10.4
% 
2.88 
(2.09
-
3.95) 
MCA 1/3 
involve-
ment no 
[n=1487] 
51.1
%  32.9% 
2.38 
(1.89-
2.98) 
0.49
5 
31.6
%  18.3% 
2.27 
(1.70-
3.03) 
0.96
2 
52.5
%  26.3% 
3.13 
(2.50-
3.91) 
0.3
59 
22.2
%  10.4% 
2.93 
(2.14
-
4.02) 
0.45
8 
MCA 1/3 
involve-
ment yes 
[n=229] 
27.4
%  17.9% 
2.23 
(1.07-
4.65) 
15.0
%  7.7% 
3.16 
(1.08-
9.24) 
29.1
%  9.9% 
4.74 
(2.12-
10.62) 
3.9
%  2.7% 
0.08 
(0.00
-215) 
Hyper-
dense 
sign no 
[n=692] 
45.7
%  30.8% 
1.95 
(1.39-
2.70) 
0.03
4 
28.0
%  13.6%  2.40 (1.65 (3.50) 
0.99
7 
48.5
%  22.9% 
4.59 
(1.65-
12.23) 
0.4
16 
18.6
%  8.8% 
2.83 
(1.71
-
4.70)  0.96
2 Hyper-
dense 
sign yes 
[n=682] 
46.6
%  23.8% 
3.20 
(2.26-
4.53) 
27.7
%  14.0% 
2.47 
(1.70-
3.60) 
50.1
%  22.3% 
3.67 
(2.58-
5.20) 
20.9
%  9.1% 
3.03 
(1.83
-
5.02) 
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Clot 
burden 
score 0 to 
4 
[n=1026] 
41.5
%  23.4% 
2.84 
(2.07-
3.90) 
0.03
8 
24.4
%  12.1% 
2.69 
(1.79-
4.05) 
0.24
4 
47.7
%  20.0% 
3.61 
(2.71-
4.81) 
0.0
82 
16.9
%  6.2% 
4.14 
(2.56
-
6.68) 
0.04
2 
Clot 
burden 
score 5 to 
7 [n=475] 
57.4
%  45.4% 
1.77 
(1.19-
2.64) 
38.7
%  25.8% 
1.94 
(1.17-
3.19) 
52.2
%  33.6% 
2.41 
(1.59-
3.64) 
24.9
%  16.5% 
1.82 
(1.11
-
2.96) 
Clot 
burden 
score 8 to 
10 
[n=135] 
58.0
%  40.9% 
2.31 
(1.06-
5.04) 
36.2
%  22.7% 
2.30 
(0.72-
7.30) 
47.8
%  21.9% 
3.77 
(1.64-
8.64) 
26.1
%  9.4% 
3.70 
(1.21
-
11.30
) 
ICA 
[n=440]  33.0%  15.5% 
2.91 
(1.79-
4.73) 
0.24
9 
17.8
%  8.4% 
2.26 
(1.23-
4.15) 
0.90
9 
42.2
%  15.1% 
3.87 
(2.41-
6.21) 
0.2
42 
9.3
%  3.7% 
3.05 
(1.23
-
7.60) 
0.41
6 
Proximal 
M1 
[n=631] 
47.0
%  28.9% 
2.63 
(1.76-
3.93) 
27.8
%  15.4% 
2.42 
(1.43-
4.09) 
51.1
%  24.6% 
3.18 
(2.25-
4.50) 
21.9
%  8.6% 
3.81 
(2.23
-
6.51) 
Distal M1 
[n=428]  58.6%  48.1% 
1.67 
(1.10-
2.54) 
40.5
%  26.4% 
2.00 
(1.16-
3.43) 
52.6
%  34.6% 
2.29 
(1.46-
3.59) 
25.2
%  17.2% 
1.84 
(1.09
-
3.12) 
M2 
[n=130]  58.2%  39.7% 
2.35 
(1.07-
5.14) 
37.3
%  20.6% 
2.49 
(0.80-
7.75) 
47.8
%  18.0% 
4.73 
(2.00-
11.21) 
26.9
%  8.2% 
4.38 
(1.39
-
13.82
) 
Collateral 
grade 0 or 
1 [n=211] 
27.1
%  13.9% 
1.80 
(0.69-
4.71) 
0.40
2 
15.6
%  5.2% 
4.05 
(1.03-
15.91) 
0.62
3 
31.9
%  18.3% 
2.18 
(1.04-
4.55) 
0.1
45 
11.2
%  2.9% 
3.47 
(0.48
-
25.12
) 
0.97
5 Collateral grade 2 
[n=552] 
44.0
%  28.5% 
2.49 
(1.68-
3.69) 
27.7
%  14.1% 
2.90 
(1.80-
4.69) 
47.3
%  23.8% 
3.01 
(2.07-
4.39) 
20.4
%  8.8% 
3.92 
(2.20
-
6.99) 
Collateral 
grade 3 
[n=515] 
55.4
%  33.5% 
2.63 
(1.80-
3.84) 
33.3
%  17.9% 
2.25 
(1.47-
3.45) 
56.3
%  23.3% 
4.30 
(2.89-
6.40) 
21.9
%  9.5% 
2.95 
(1.71
-
5.10) 
 *defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0‐1 24 hours after stroke. 
mRS, the modified Rankin Scale; CT, Computed Tomography; MRI, Magnetic Resonance Imaging; CTA, Computed Tomography Angiography; 
MRA, Magnetic Resonance Angiography; NIHSS, National Institute of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; 
ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 2: Endovascular treatment effect by baseline imaging variable categories on secondary outcomes. 
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Subgroup  Endovascular group  Control group  Odds Ratio (95% CI)  p-value (subgroup)  p-value  (interaction) % (n/N)  % (n/N) 
Baseline ASPECTS              
   0-4
 
19.2% (10/52)
 
4.5% (3/66)
 
5.00 (1.30,19.25)
 
0.016
 
 
   5-7
 
3.8% (12/319)
 
3.7% (11/297)
 
1.02 (0.44, 2.34)
 
1
 
0.026
 
   8-10
 
2.1% (10/473)
 
3.4% (17/498)
 
0.61 (0.28, 1.35)
 
0.245
 
 
   0-2  11.1% (1/9)  4.2% (1/24)  2.88 (0.16, 51.53)  0.477   
   3-5  14.7% (14/95)  3.4% (3/87)  4.84 (1.27, 27.03)  0.010  0.008 
   6-10  2.3% (17/740)  3.6% (27/750)  0.63 (0.32, 1.21)  0.168   
MCA > 1/3 involvement             
   No  2.3% (17/736)  3.6% (27/748)  0.63 (0.34, 1.17)  0.168  0.002
    Yes  13.9% (15/108)  3.5% (4/113)  4.40 (1.41, 13.70)  0.007 
Hyperdense sign             
   No  3.3% (12/360)  3.5% (14/401)  0.95 (0.43, 2.09)  1  0.865
    Yes  4.5% (16/353)  5.2% (17/328)  0.87 (0.43, 1.75)  0.724 
Clot burden score             
   8-10  0.0% (0/69)  7.5% (5/67)  0.00 (0.00, 0.95)  0.027   
   5-7  4.7% (11/233)  2.9% (7/240)  1.65 (0.63, 4.33)  0.344 
0.063
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   0-4  3.4% (17/503)  3.1% (16/513)  1.09 (0.54, 2.18)  0.861   
Occlusion location             
   ICA  3.3% (7/210)  2.6% (6/227)  1.27 (0.42, 3.84)  0.781 
0.154
 
   Proximal M1  3.9% (12/307)  3.5% (11/318)  1.14 (0.49, 2.61)  0.834 
   Distal M1  4.1% (9/218)  2.9% (6/207)  1.44 (0.50, 4.13)  0.603 
   M2  0.0% (0/67)  7.8% (5/64)  0.00 (0.00, 0.96)  0.026 
Collateral grade             
3  3.1% (8/259)  2.7% (7/259)  1.15 (0.41, 3.21)  1   
2  3.2% (9/281)  2.9% (8/275)  1.10 (0.42, 2.91)  1 
0.443
 
   0-1  5.3% (5/94)  10.5% (12/114)  0.48 (0.16, 1.41)  0.209   
ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 3: Symptomatic intracerebral hemorrhage (sICH) rate by treatment and baseline imaging variable 
categories  
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FIGURES 
 
Figure 1. Endovascular treatment effect by baseline imaging variable categories on primary outcome (mRS shift at 90 
days) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
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Figure 2. Panel A shows endovascular treatment effect by individual baseline ASPECTS grades on primary outcome 
(mRS shift at 90 days). There was no statistical evidence of heterogeneity across ASPECTS categories for the 
relationship between treatment and primary outcome. Panel B shows exploratory analysis informed by pre-specified 
analyses of treatment effect by individual baseline ASPECTS grades and combines individual ASPECTS grades into 
categories (6-10 vs. 3-5 and 0-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, 
lower confidence limit; UCL, upper confidence limit. 
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Figure 3: Endovascular treatment effect by baseline imaging variable categories on safety outcomes, namely, mortality 
at 90 days and symptomatic ICH incidence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
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II. FIGURES 
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eFigure 1: PRISMA IPD flow diagram illustrating study selection. 
 
 3 
eFigure 2:  Flow chart describing number of patients assessed for imaging variable at baseline and rea-
sons for exclusion. Missing patients were not included in the  different analysis of each imaging variable. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
eFigure 3: Distribution of modified Rankin Scale at 90 days stratified by ASPECTS categories in the 
endovascular and control groups (numbers within the horizontal bars represent percentages). 
 
  
 
 
 
 
eFigure 4:  Distribution of modified Rankin Scale at 90 days stratified by thrombus location in the endo-
vascular and control groups (numbers within the horizontal bars represent percentages). 
 
  
 
 
 
 5 
 
 
eFigure 5:  Distribution of modified Rankin Scale at 90 days stratified by collateral circulation score cat-
egories in the endovascular and control groups (numbers within the horizontal bars represent percent-
ages). 
 
  
 
 
eFigure 6:  Distribution of modified Rankin Scale at 90 days stratified by presence or absence of hyper-
dense sign on CT in the endovascular and control groups (numbers within the horizontal bars represent 
percentages). 
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eFigure 7:  Distribution of modified Rankin Scale at 90 days stratified by presence or absence of early 
ischemic changes in 1/3rd of MCA territory in the endovascular and control groups (numbers within the 
horizontal bars represent percentages). 
 
  
 
eFigure 8:  Distribution of modified Rankin Scale at 90 days stratified by clot burden score categories in 
the endovascular and control groups (numbers within the horizontal bars represent percentages). 
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eFigure 9: Endovascular treatment effect by baseline imaging variable categories on primary outcome 
(mRS at 90 days) stratified by imaging modality (CT vs. MRI). Treatment effect is assessed through the 
common odds ratio for mRS shift. 
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eFigure 10: Endovascular treatment effect by baseline imaging variable categories on imaging safety 
outcome, namely, Parenchymal Hemorrhage Type 2. Treatment effect is assessed through the common 
odds ratio for mRS shift. 
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I. TABLES 
 
eTable 1: Qualitative assessment of between-trial differences in population, sampling frame and opera-
tional definitions of treatment groups. 
 
 MR CLEAN  ESCAPE  EXTEND IA  SWIFT PRIME  RE
Population 
Continent  Europe  North America, Europe, East Asia  Oceania  North America and Eu-rope  Eur
 10 
Country  Netherlands  Multiple  Australia and New Zea-land  Multiple  Spa
Sampling Frame 
Imaging Criteria 
Modality  NCCT/CTA  NCCT/CTA *CTP op-tional  NCCT/CTA/CTP *MRI optional  NCCT/CTA/CTP *MRI optional  NCtion
Occlusion Site  ICA M1 M2  ICA M1  ICA M1 M2  ICA M1  ICA
Ischaemic Core Defini-
tion  Not used  ASPECTS 6-10 Good Collaterals  CTP mismatch and is-chemic core <70mL 
CTP and NCCT AS-
PECTS criteria (modified 
protocol)  AS
Clinical Criteria 
Age (years)  ≥18  ≥18  ≥18  18-85 (later amended to 18-80)   
18-
allo
PE
Baseline Stroke Severity  NIHSS ≥2  NIHSS ≥6  No limit  NIHSS 8-29  NIH
Time to randomization  6 hours  12 hours  6 hours  6 hours  8 h
Definition of sICH  Any ICH and ≥4-point increase NIHSS Any ICH judged to cause ≥2-point increase NIHSS  PH2/SAH + ≥4-point in-crease NIHSS  Any PH/SAH/IVH + ≥4-point increase NIHSS  PHinc
Control Group 
 Standard care  Standard care  Standard care in IV altep-lase eligible patients   Standard care in IV altep-lase eligible patients  Sta
Intervention Group 
Wait for response to IV 
alteplase  No  No  No  No  Ye
Pre-specified time met-
rics  No  Yes  No  Yes  Ye
Type of Devices  Any  Any  Solitaire  Solitaire  Sol
 
 
 
 
 
NCCT, Non contrast CT; CTA, CT angiography; CTP, CT Perfusion; MRI, Magnetic Resonance Imag-
ing; ICA, Internal Carotid Artery; MCA,  Middle Cerebral Artery; ASPECTS, Alberta Stroke Program 
Early CT Score; PH, Parenchymal Hemorrhage; SAH, Subarachnoid hemorrhage; IVH, Intra-ventricular 
Hemorrhage; NIHSS, National Institute of Health Stroke Scale; IV, intravenous. 
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eTable 2: Endovascular treatment effect in patients with large ischemic core at baseline defined post-hoc 
using different ASPECTS scores on CT and/or MRI. 
 
Large extent of early ischemic change at 
baseline*   common Odds Ratio  95% Confidence Interval  p-value 
ASPECTS 0 to 4 [n=126]  2.15  1.06 - 4.37  0.036 
ASPECTS 0 to 4 CT or 0 to 3 MR [n=105]  1.9  0.86 - 4.2  0.12 
ASPECTS 0 to 4 CT or 0 to 2 MR [n=89]  1.38  0.58 - 3.29  0.47 
ASPECTS 0 to 4 CT only [n=65]  1.68  0.58 - 4.87  0.34 
 
 
 
 
 
*Post-hoc definitions of large early ischemic change extent combining using different ASPECTS cut-
points for CT and MRI. Statistical significance is only obtained once all CT/MR data are used for AS-
PECTS 0-4. Since most MRI data are from one study (THRACE), we are not confident that one can relia-
bly distinguish MRI specific effect from a trial specific effect, especially among subgroups of this size. 
 
 
 
eTable 3: sICH numbers in patients who underwent EVT stratified by reperfusion status (mTICI>=2b or 
not) and ASPECTS categories 0-4. 
 
mTICI<2b  mTICI>=2b 
ASPECTS  sICH  ASPECTS  sICH 
No  Yes  Total  No  Yes  Total 
0  1  0  1  0  0  1  1 
1  1  0  1  1  0  0  0 
2  2  0  2  2  3  0  3 
3  7  2  9  3  2  0  2 
4  1  4  5  4  21  2  23 
Total   12  6  18  Total   26  3  29 
 
 
 
IV. STATISTICAL ANALYSIS PLAN 
A) Objective 
Endovascular treatment of acute stroke has been proven in randomized controlled trials as the standard of 
care for patients with proximal anterior circulation occlusions. This new evidence in the treatment of 
 12 
acute large vessel ischemic stroke has created a need for effective and rapid selection of stroke patients 
who will most benefit from endovascular stroke therapy.  
Imaging features have been proven to play a role in clinical outcome. We want to take advantage of the 
data accumulated through the different clinical trials to study if there are chances to improve the imaging 
protocol to adequately select patients that will benefit endovascular treatment.  
From the Hermes (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) neu-
roimaging studies of all patients in the MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, EXTEND 
IA, PISTE and THRACE trials, we propose to determine whether imaging features at baseline that meas-
ure extent of parenchymal involvement, thrombus and collaterals are associated with response to endo-
vascular treatment. We also seek to extend safety information by looking for subgroups of patients (iden-
tified using imaging) who may a higher risk of complications from endovascular therapy. 
B) Imaging variables 
Parenchymal Imaging 
a) ASPECTS on non-contrast CT read blinded to other baseline imaging modalities.  
We will attempt analysis based on pre-specified ASPECTS categories, namely, 8-10, 5-7 and 0-
4. If sample size is sufficient across all ASPECTS grades, we will also attempt analysis by each 
ASPECTS grade i.e. 0,1,2,3,4,5,6,7,8,9,10 to identify an ASPECTS cut-point that suggests to 
futility of endovascular treatment. The majority of baseline imaging in the HERMES data is 
non-contrast CT. When MRI is the baseline imaging modality, ASPECTS will be defined on 
baseline DWI. A region will be considered as involved if DWI lesion affects > 30% of the AS-
PECTS region.  
b) Extent of early ischemic change in the MCA territory dichotomized as > or < 33% MCA terri-
tory. 
 
Thrombus Imaging 
a) Location and nature of baseline thrombus on CTA (or if CTA not available on MRA). 
We will attempt analysis based on pre-specified baseline occlusion categories i.e. (ICA, proxi-
mal M1 MCA, distal M1 MCA, M2 MCA and beyond). M1 MCA segment is defined as the first 
branch of the intracranial ICA which courses horizontally from its branching point off the ICA 
through the sphenoidal section of the Sylvian fissure up to the first bifurcation distal to the origin 
of the lenticulostriate arteries in the distal aspect of the sphenoidal Sylvian fissure. The M2 
MCA segment was defined as distal to the MCA bifurcation and into the operculo-insular seg-
ment of the Sylvian fissure. Tandem occlusion was defined by CTA/MRA as occlusion of extra-
cranial ICA with intracranial (ICA, M1-MCA, M2-MCA). 
b) Hyperdense artery sign presence, location and extent on non-contrast CT. Differential out-
comes will be reported by above categories. 
c) Clot burden score (CBS) on CTA (or if CTA unavailable, on MRA). The CBS is a scoring sys-
tem to define the extent of thrombus found in the proximal anterior circulation by location and 
is scored on a scale of 0–10. The thrombus can be partially or completely occlusive. A score of 
10 is normal, implying clot absence. A score of 0 implies complete multi-segment vessel oc-
clusion.  
Collateral Circulation Imaging 
Collateral imaging is best done on multi-phase CTA or if not available, on appropriately phase weighted 
single-phase CTA. Analysis of collateral status and its relationship to final outcomes by treatment arm 
will be reported for pre-specified collateral grade categories: Grade 0-1 poor, grade 2: intermediate and 
grade 3: good as well as in a granular manner for each category.  
         C) Primary Outcome 
The modified Rankin Scale (mRS) at 3 months from onset. 
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        D) Secondary Outcomes   
Secondary efficacy outcomes were functional independence (mRS 0–2) at 90 days, excellent functional 
outcome (mRS 0–1) at 90 days, dramatic neurological improvement (defined as neurological improve-
ment of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after stroke) and patients in the endovascular 
group with complete arterial recanalization [defined as a modified Thrombolysis In Cerebral Infarction 
(mTICI) score 2b or 3]. Safety outcomes included the symptomatic intracranial hemorrhage (sICH; de-
fined by each trial), parenchymal hematoma type 2 (PH2; blood clot occupying >30% of the infarcted ter-
ritory with substantial mass effect) within 5 days of randomization, and mortality within 90 days. 
E) Primary Analyses  
All analyses will be based on the “as randomized” population. To account for between trial differences 
when pooling patient level data, mixed-effects modeling will be used for all analyses, with fixed effects 
for parameters of interest and “trial” and the interaction term “trial*treatment” as random effects variables 
in all models. Regression models will include fixed effects (age, sex, NIHSS score at admission, intrave-
nous alteplase use and time from onset to randomization) and multiplicative interaction terms to test if 
pre-specified baseline-imaging features modified the effect of treatment allocation on pre-defined out-
comes. The primary analyses will try to ascertain if baseline imaging categorization modifies the effect of 
treatment on mRS at 90 days when adjusted for pre-specified co-variates. Primary analysis will use ordi-
nal logistic regression adjusted for age, sex, NIHSS score at admission, intravenous alteplase (yes/no) and 
time from onset to randomization. It will include interaction terms testing if imaging categorization at 
baseline (parenchymal imaging, thrombus imaging and collateral imaging independently) modifies the 
relationship between treatment and outcome. If statistically significant interaction is noted, category spe-
cific effects will be reported (in text and using figures). 
F) Secondary Analysis  
Depending on the nature and distribution of secondary outcomes specified above, secondary analyses will 
use appropriate regression techniques adjusted for age, sex, NIHSS score at admission, intravenous altep-
lase (yes/no) and time from onset to randomization to analyze if the above-defined imaging categories 
modify the effect of treatment on outcome. Multiplicative interaction terms will be used to test for these 
statistical interactions. If statistically significant interaction is noted, category specific effects will be re-
ported (in text and using figures). For primary and secondary analyses, forest plots with each imaging cat-
egory specific effect including interaction p value will be reported.  
Sensitivity analyses as above will be performed for patients imaged using CT vs. MRI. 
  
